Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01162499 · ClinicalTrials.gov registry record · NA
Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia
A NA study, sponsored by Diva De Leon.
- Completed
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT01162499 is a NA study that has completed, run by Diva De Leon. The registered enrollment target is 7 participants.
The verdict
NCT01162499, a NA study, has completed, sponsored by Diva De Leon.
- COMPLETED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
It has been proposed that the rapid gastric emptying of carbohydrate containing fluids into the intestine causes hyperglycemia followed by reactive hypoglycemia. The investigators have shown that glucagon-like peptide-1 (GLP-1) secretion in response to a glucose load is increased in children with Post-prandial hypoglycemia (PPH). This is a proof of concept study to investigate the causative role of GLP-1 in the pathophysiology of PPH after fundoplication by evaluating the effects of GLP-1 receptor antagonism on metabolic variables after a mixed meal. Hypothesis: In children with post-prandial hypoglycemia after fundoplication, antagonism of the GLP-1 receptor by exendin-(9-39) will elevate nadir blood glucose levels after a meal challenge and prevent post-prandial hypoglycemia.
Interventions
- OTHER Vehicle
- DRUG Exendin-(9-39)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2010-04 |
| Est. Completion | 2014-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01162499
The ClinicalTrials.gov registry entry for NCT01162499 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Diva De Leon, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT01162499 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01162499 about?
NCT01162499 is a clinical study titled "Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia". It has been proposed that the rapid gastric emptying of carbohydrate containing fluids into the intestine causes hyperglycemia followed by reactive hypoglycemia. The investigators have shown that glucagon-like peptide-1 (GLP-1) secretion in response to a glucose load is increased in children with Po...
What is the current status of trial NCT01162499?
This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2010-04. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01162499?
The interventions under investigation include: Vehicle (OTHER), Exendin-(9-39) (DRUG).
Who is sponsoring clinical trial NCT01162499?
This trial is sponsored by Diva De Leon, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.